Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Apotea, Webcast, Q2'26

By Inderes7/17/2026, 7:30 AM
Apotea

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Sarah Ahnström
00:00 - 00:31

Good morning, everyone, and welcome to the presentation of Apotea's Q2 2026 report. As usual, we will start with a presentation. And after the presentation is done, we will move on to a Q&A with spoken questions. Today's presenters are Pär Svärdson, CEO and co-founder, Johan Mårild, CFO, and myself, Sarah Ahnström, CCO. And we will begin with some highlights of the quarterly figures.

Pär Svärdson
00:33 - 00:44

Hello. I think we have had a good quarter with good profitability and stable growth. So Johan, please show us the figures.

Johan Mårild
00:45 - 01:04

Yes. We had net revenue of 2.026 billion in the quarter and a growth of 10.9%. We had strong profitability in the quarter. We increased adjusted EBIT and had an adjusted EBIT margin of 5.2%.

Pär Svärdson
01:07 - 01:42

And if we look at the second quarter, I think we have had good progress on our growth initiatives. It consists of a lot of small projects ranging from assortment and stock levels to the customer journey and so on. But I think we have a good speed. It takes some time. But we will absolutely see the effect of that in the coming year. So please show us a little bit more about them.

Sarah Ahnström
01:43 - 03:03

Perfect. Exactly. Some examples of these sales initiatives. One is, of course, the launch of apotea.no. At the end of May. We did a soft launch of the site, and we are now selling our beauty and health assortment into the Norwegian market. During this quarter, we have also begun some marketing activities on a small scale and started to scale up sales. And we have gone from a few orders each day to a couple of hundreds. And the ambition is, of course, to continue to strengthen our position in the Norwegian market. And we have also continued to develop, or I should say scale up, production in our new fulfillment centre in Varberg, and we are working quite a lot on optimizing our operations. So we will continue to do so. We are quite pleased to see that a higher share of larger orders are now being handled by this automated facility. We also have a new high score. During the quarter, we reached a production level of more than 30,000 orders per day. At the end of May, we also rolled out a company-wide D-share program, enabling our colleagues from the office, prescribed Rx hubs, and the fulfilment centre to participate, which we are very happy about.

Johan Mårild
03:04 - 09:04

We had revenue in the quarter approaching a rolling 12-month revenue of over 7.6 billion, and an adjusted EBIT margin for the same period of 4.2%, which was in line with the rolling 12-month number in Q1. Let's take a look at the numbers in more detail. We had revenues exceeding 2 billion in the quarter. As mentioned, we had a stable growth of 10.9%. We had a slightly higher growth rate in Rx. But we had stable growth in both OTC and traded goods, as well as in Rx. Rx continued to increase its share of the revenues in the quarter. To the right, you can see our gross margin development. And we had a stable gross margin in the quarter. We had a strong profitability in the quarter. We increased adjusted EBIT to 105 million SEK, despite increased depreciation of more than 17 million kronor. And we had an adjusted EBIT margin of 5.2%. If you look to the right, you can see our selected operating costs as a percentage of revenue. And as expected, the depreciation and amortization increased. And that is the result of the fulfillment center in Varberg, which was established last year. At the same time, we have improved efficiency. As you can see, there is a decline in personnel and other external expenses as a percentage of revenue. The improved efficiency is the result of continued good cost control. But we also get better cost leverage as we increase capacity utilization. If you look at the year-to-date figures, we had a stable growth of 10.7% for the first half of the year. Also looking at the first half year, Rx grew slightly higher than OTC and traded goods and increased its share of revenues. Adjusted EBIT increased to 206 million SEK, and we had stable profitability. And that corresponds to an adjusted EBIT margin of 5.2%. And also for the first half year, we have also seen a high increase. As expected, depreciation and amortization for the first half year increased by roughly 35 million SEK. We had lower operating cash flow in Q2 as well as year-to-date. The operating cash flow was impacted by inventory. And the inventory has increased in part due to inventory buildup in Varberg, but also temporary measures to ensure robustness in the supply chain, as we have highlighted before. To the right, you can see our CapEx; following the completion of the fulfilment centre in Varberg, we have had a significantly lower investment pace in the half-year. We have very limited investments, and as we now are scaling up the production in Varberg, we are at the same time evaluating and figuring out what new investments are best suited for these operations. Investments are likely to remain low this year. However, if you look at the longer period between investments related to new fulfilment centres, we are still expecting a yearly average of CapEx of 50 to 70 million SEK. We had inventory of slightly above 850 million SEK at the end of June. Over the course of the last year, we have increased inventory, mainly due to the buildup of inventory in Varberg, and as a consequence of the increased inventory, inventory turnover has also declined. We expect to gradually increase the inventory turnover as capacity utilization increases, but also by further optimization. Let's take a look at the return on capital employed. We have a high return on capital employed of over 27 percent, although it has declined over the past year as a result of the fulfillment centre in Varberg, and to the right, you can see our net debt and net cash position. At the end of June, we continued to have a very strong balance sheet and a cash position of 104 million. And this is despite an increased inventory and also dividend paid out in Q2 of roughly 62 million SEK.

Pär Svärdson
09:08 - 09:57

Yeah. And if we look at our focus ahead, we will continue to focus on growth initiatives, but also to build the pharmacy of tomorrow. And when we say building the pharmacy of tomorrow, it means that we have a continuous journey to improve everything to make it better for the customer. So a lot of these small everyday steps are how we succeed. It is a forever journey. I think having a goal that prioritizes constant change is very important in our business, and we will continue to focus on that. Sarah will give us some examples.

Sarah Ahnström
09:59 - 11:31

Exactly. Growth remains our main focus also going forward. I think we have to look through all parts of the customer journey to make sure that we are excellent in every step. And that includes, as I mentioned in the beginning, it includes the assortment, the pricing features on the site, the information regarding the deliveries, and so on. We have to be excellent in all aspects and improve even further. And we will of course also focus on apotea.no. As you said in the beginning, we have just started with the marketing activities. So we will start to or continue to increase the marketing activities and step by step also increase the sales. And we want to make sure that we continue to develop the customer offering in Norway to ensure that it remains a strong proposition. Also in the Norwegian market. We also want to continue to focus on and improve our offering of prescribed medicine. And we want to make it even easier for the customers to order online. We have previously provided examples such as expanding the assortment of prescribed medicine that demand cold storage, but also expanding the deliveries of cold chain products. And we also mentioned digital inhalation guidance as a pharmaceutical service and those types of initiatives. We will continue to launch initiatives to make sure that we are a pharmacy of tomorrow also going forward. And that was the end of the presentation. So we will move on to a Q&A with spoken questions.

Operator
11:36 - 11:41

The next question comes from Benjamin Wahlstedt from ABG Sundal Collier. Please go ahead.

Pär Svärdson
11:44 - 11:45

Hello.

Benjamin Wahlstedt
11:45 - 12:02

I was wondering, firstly, if you could elaborate on the organic growth trajectory a bit. You have previously commented that you expect gradually higher growth rates throughout the year, but also that it takes some time. So I was wondering just how should we weigh these statements against each other, please?

Pär Svärdson
12:04 - 12:59

I can start by discussing it. I mean, a lot of these initiatives are small steps, and first you need to design it and build it, and then the customer realizes that it is easier. So it takes some time. I believe we can increase growth by a single-digit percentage every quarter or something similar. But it takes time. But over about one year, I think you can see a big difference, but it takes some time. I think it takes too much time sometimes, but it does. Do you have any more comments on that, Sarah and Johan?

Johan Mårild
13:00 - 13:09

No, I think as mentioned, growth initiatives are our main focus and we're not satisfied with the growth rate.

Benjamin Wahlstedt
13:13 - 13:31

Thank you very much. Second, will you comment on a gradual ramping up in marketing spend related to Norway? And I was just wondering, what sort of magnitudes are you talking about here? Is there something that you expect to move company profits?

Sarah Ahnström
13:33 - 13:33

I think.

Pär Svärdson
13:35 - 13:36

Sorry.

Sarah Ahnström
13:36 - 13:49

Just a short note. We are still in the very beginning of it. And I think the marketing activities are so far on a small scale, and we will ramp it up very gradually and step by step to just make that clear.

Pär Svärdson
13:50 - 14:07

And compared to Sweden, it is almost zero. So, if you take it from a real result perspective, it is nothing. But for Norway it's a big step. Yeah.

Benjamin Wahlstedt
14:07 - 15:02

Perfect. And then I was wondering about the incentive program structure. I understand this is not something you decide all by yourself. It is a shareholder decision. But then again, you also own a large part of the total shares both directly and indirectly. You start receiving EBIT-related shares already at a 3% margin all the way until 2028. A 3% margin in 2028 looks like a fairly guaranteed payday. On the other hand, your growth targets look more forward-leaning. Growth incentive shares start kicking in at growth of 15%. So should we expect you to dig a bit deeper into the margins to ramp up growth in the near term? Is that how we should interpret the incentive program, or what are we missing?

Pär Svärdson
15:03 - 16:02

We tried to correlate the incentive program with the financial targets, because I think it is important to have financial incentive programs that correlate to what we tell the market, as we want them to be aligned. Otherwise, it sounds very strange. So that is what we have tried to do. I mean, the D-share program that we also launched was just normal shares. But with a technical construction, it is easier to buy them. But I think it is important that our employees have shares as well and share the same goal that the market does, because then we can have the same targets. Johan, do you want to add something to that?

Johan Mårild
16:02 - 16:20

No. Yes, yes. As mentioned, the shares follow a hurdle share construction. And following this, it is more or less the same structure that we had before with the C shares. And they were also offered company-wide, as we've done in the past.

Benjamin Wahlstedt
16:25 - 16:33

All right. So we should not take the levels of the targets as suggesting a change in strategy from here on out.

Johan Mårild
16:34 - 16:35

No, no, no.

Pär Svärdson
16:35 - 16:37

Follow the financial targets.

Benjamin Wahlstedt
16:38 - 16:41

All right. Perfect. That is all I have for now. Thank you very much.

Sarah Ahnström
16:42 - 16:42

Thank you.

Unknown 1
16:42 - 16:43

Thank you.

Operator
16:45 - 16:50

The next question comes from Amina Ashraf from Danske Bank. Please go ahead.

Amina Ashraf
16:52 - 17:13

Good morning, and thank you for taking my question. I am actually very interested to hear more about your beauty and health assortment. You mentioned that there is significant upside potential in the expansion in Norway. So maybe you can shed some light on how different the consumer behavior is regarding beauty consumption in Norway versus Sweden.

Sarah Ahnström
17:16 - 17:49

I think it is actually at too early a stage to discuss the differences in too much detail. I think we are too early on to make any assumptions based on the consumer so far. But what we can say is that we see great potential in Norway. And we also see great potential both in the pharmacy market, where we are present through Apotea and also through the beauty and health assortment through apotea.no. So I think there is great potential in the Norwegian market. And we are still quite small. And we expect to have a growth path in the Norwegian market.

Unknown 1
17:51 - 17:51

Yeah.

Amina Ashraf
17:52 - 17:53

It has only been a short time.

Unknown 1
17:54 - 17:54

No, I am.

Amina Ashraf
17:55 - 17:55

Sorry.

Unknown 1
17:55 - 17:55

Go ahead.

Johan Mårild
17:55 - 18:34

Just to add to that, we have a pharmacy offering in Norway. And with the launch. Soft launch of apotea.no in the end of April. We are also complementing that. And with the beauty and health assortment that is available to the Swedish customers. We have a fairly large beauty and health sales and a strong position in those segments in Sweden. And of course, we see a potential to further leverage that strength in the Norwegian market that we regard as attractive.

Unknown 1
18:36 - 18:36

Mm.

Amina Ashraf
18:36 - 19:03

No, I completely agree. My market research shows that Norway is a very attractive market as well. But if I ask you then with regards to how much beauty contributes to your total revenues, if I go scrape your website in Sweden, correct me if I'm wrong, but approximately 41% of your online assortment is beauty and health. Are you expecting that to be the same in Norway as well?

Sarah Ahnström
19:04 - 19:34

It is a fair share of our total sales and we see great potential in it, both in the Swedish market and the Norwegian market. And I think we have two different offerings in the Norwegian market currently. One is a very specific pharmacy offering with an assortment related to the pharmacy industry. The other one is a pure beauty and health assortment that we ship currently from our facility. So it is a related assortment to the Swedish one. If that answers your question.

Amina Ashraf
19:37 - 19:45

All right. And given that information, could you shed any light compared to your total revenues? What percentage of our total revenue does beauty and health represent?

Sarah Ahnström
19:46 - 19:59

We haven't disclosed that in specific. We have done it historically a couple of years ago, I would say, and then we stated that it was past 1 billion, but we haven't shared that number since then.

Johan Mårild
19:59 - 20:31

But we can say that there is healthy growth in those segments. And just to be clear, it is not one segment. It is a lot of different categories that make up these segments. It is a natural part of being a pharmacy and also Apotea for a long time, being a frontrunner in expanding and strengthening the role of the pharmacy and including health and beauty products in that offering.

Amina Ashraf
20:32 - 20:38

Yeah, absolutely. So, what percentage of the total sales did that historical number represent? What percentage of the total sales was that?

Sarah Ahnström
20:40 - 20:52

I think it's not fair to say, because I'm not sure exactly when we released that figure, but it's a press release that you can find, and we haven't disclosed it since.

Amina Ashraf
20:52 - 20:53

All right.

Sarah Ahnström
20:54 - 20:54

So it is.

Amina Ashraf
20:54 - 20:55

Would it be fair?

Unknown 1
20:56 - 20:56

Sorry.

Amina Ashraf
20:58 - 21:08

I was just going to say, would it be fair to assume that it's in line with the percentage of the assortment? I mean, the 41% that my scraping talents tell me.

Johan Mårild
21:09 - 21:26

I think it's difficult to look for an assortment number because mascara and lipstick have a lot of SKUs. So, it is difficult to say, and I do not have the percentage on top of my mind, actually. But yes.

Pär Svärdson
21:27 - 22:04

I mean, you said 41% of the total number of SKUs. And when we mentioned this 1 billion, it was likely closer to half of that in relation to us. I mean, because on the pharmacy side, you have like painkillers and OTC products that sell a lot. So I think you can more likely divide it by two. It is a rough estimate, but that is a very rough number. But then you have something.

Amina Ashraf
22:08 - 22:13

All right. Well, thank you so much. That was very exciting to hear about the beauty and health assortment.

Sarah Ahnström
22:14 - 22:29

Thank you. That was also the last question for today. So thank you very much for listening to the presentation. Despite the very sunny and warm weather in Sweden. And thank you for today.

Pär Svärdson
22:30 - 22:31

Thank you very much.

Johan Mårild
22:32 - 22:33

Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…